MEDIPAL HOLDINGS (7459) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The cumulative Q3 results were characterized by higher revenue but lower operating income, while Ordinary Income and Net Income were boosted by non-operating income and gains on the sale of investment securities. Revenue was ¥2兆9,116.7B (up +3.7% year on year), and Operating Income was ¥431.8B (down △4.8%), leaving the Operating Income margin at 1.5%, roughly unchanged from the previous year. Meanwhile, Ordinary Income was ¥613.1B (up +8.1%) and Net Income was ¥458.1B (up +1.3%), securing profit growth; however, this was attributable to ¥201.6B in non-operating income, including equity-method investment gains and dividend income, as well as extraordinary gains that included ¥99.7B in gains on the sale of investment securities, rather than an improvement in operating profitability. The decline in the segment profit margin of the core Wholesale Business of Prescription Pharmaceuticals, etc., was the primary cause of the consolidated decline in Operating Income.

Factors Affecting Results

【Revenue】Revenue was ¥2兆9,116.7B, up +3.7% year on year. The Wholesale Business of Prescription Pharmaceuticals, etc. (64.3% of revenue composition, external revenue of ¥1兆8,722.6B, up +3.6%) and the Wholesale Business of Cosmetics, Daily Necessities, and OTC Pharmaceuticals (32.6% of revenue composition, ¥9,504.2B, up +4.4%) drove growth. The Related Businesses, including the Wholesale Business of Veterinary Pharmaceuticals and Food-Processing Raw Materials (3.1% of revenue composition, ¥889.9B, down △0.5%), recorded a slight decline in revenue.

【Profit and Loss】Operating Income was ¥431.8B, down △4.8% year on year, resulting in lower profit despite higher revenue. The primary factor was a decline in the profit margin of the largest segment, the Wholesale Business of Prescription Pharmaceuticals, etc. (1.2%→1.0%); segment profit was ¥188.6B (down △9.6%). The Wholesale Business of Cosmetics, Daily Necessities, and OTC Pharmaceuticals also recorded higher revenue but lower profit (profit margin: 2.4%→2.3%), while the Related Businesses, including the Wholesale Business of Veterinary Pharmaceuticals and Food-Processing Raw Materials, improved its profit margin from 2.2%→2.4% and was the only segment to record higher Operating Income. Ordinary Income was ¥613.1B (up +8.1%), boosted by ¥201.6B in non-operating income, including ¥32.1B in equity-method investment gains and ¥24.2B in dividend income. After deducting extraordinary losses of ¥52.0B, including ¥45.4B in business restructuring costs, from extraordinary gains of ¥104.6B, including ¥99.7B in gains on the sale of investment securities, Profit Before Tax was ¥665.8B, resulting in Net Income of ¥458.1B (up +1.3%). In conclusion, the quarter saw higher revenue but lower operating profit, while the increases in Ordinary Income and Net Income were supported by non-operating and extraordinary gains and losses.

Segment Analysis

The Wholesale Business of Prescription Pharmaceuticals, etc. recorded revenue of ¥1,875.1B (64.3% of revenue composition, up +3.6% year on year) and segment profit of ¥188.6B (down △9.6%), with its profit margin declining to 1.0%, making it the primary cause of the consolidated decline in Operating Income. The Wholesale Business of Cosmetics, Daily Necessities, and OTC Pharmaceuticals recorded revenue of ¥950.6B (32.6% of revenue composition, up +4.4%) and segment profit of ¥219.5B (down △2.2%). Although it is the core business generating 50.8% of consolidated Operating Income, its profit margin declined from 2.4% to 2.3%. The Related Businesses, including the Wholesale Business of Veterinary Pharmaceuticals and Food-Processing Raw Materials, recorded revenue of ¥89.0B (3.1% of revenue composition, down △0.5%) and segment profit of ¥21.3B (up +8.3%), making it the only one of the three businesses to post higher profit; its profit margin improved from 2.2% to 2.4%.

Key Financial Metrics

【Profitability】The Operating Income margin of 1.5%, Gross Profit margin of 6.8%, and consolidated Net Income margin of 1.6% all reflect the low-margin, high-turnover structure characteristic of pharmaceutical and daily necessities wholesalers, while ROE was 5.8%. 【Cash Flow Quality】Accounts receivable were ¥8,822.8B, representing 60.0% of current assets, while accounts payable of ¥1兆1,062.6B represented 94.0% of current liabilities. This indicates a large working capital scale, making the management of collection and payment terms directly relevant to earnings quality. 【Investment Efficiency】Investment securities reached ¥2,127.8B and generated part of non-operating income and extraordinary gains, including ¥24.2B in dividend income and ¥99.7B in gains on the sale of investment securities; however, these should be distinguished from recurring business earnings. 【Financial Soundness】With an Equity Ratio of 38.8%, Net Assets of ¥7,839.3B, and goodwill of ¥122.3B (0.6% of total assets), the financial position is generally stable. Current assets of ¥1兆4,695.3B exceeded current liabilities of ¥1兆1,762.5B, securing positive working capital.

Cash Flow Analysis

As the data does not include detailed items from the statement of cash flows, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥2,758.7B, an increase of ¥144.6B from ¥2,614.1B in the previous year. Meanwhile, accounts receivable increased to ¥8,822.8B (¥7,635.4B in the previous year), and inventories increased to ¥2,194.5B (¥1,781.0B in the previous year), indicating an accumulation of working capital accompanying revenue growth. Accounts payable also increased to ¥1兆1,062.6B (¥9,324.7B in the previous year), with the expansion of trade payables absorbing part of the increase in working capital. Total assets expanded to ¥2兆193.7B, suggesting heightened funding needs during a business expansion phase; meanwhile, cash and deposits were maintained, and liquidity is considered generally stable.

Earnings Quality

Non-recurring factors made a significant contribution to profit growth during the quarter, making it important to distinguish recurring items from temporary items when evaluating earnings quality. Ordinary Income of ¥613.1B exceeded Operating Income of ¥431.8B by ¥181.3B, with most of this difference attributable to ¥201.6B in non-operating income, including ¥32.1B in equity-method investment gains and ¥24.2B in dividend income, rather than improved profitability in the core business. In addition, Profit Before Tax of ¥665.8B benefited from the net ¥52.7B difference between extraordinary gains of ¥104.6B, primarily consisting of ¥99.7B in gains on the sale of investment securities, and extraordinary losses of ¥52.0B, including ¥45.4B in business restructuring costs. Profit Attributable to Owners of the Parent was ¥374.1B, an increase of +3.2% year on year; however, the increase may narrow if gains on the sale of investment securities are excluded. Comprehensive Income of ¥543.8B exceeded Net Income of ¥458.1B by ¥85.8B, primarily due to ¥88.2B in valuation difference on securities. Accordingly, fluctuations in the market value of held shares also warrant attention when assessing earnings quality.

Earnings Forecasts and Guidance

The cumulative Q3 progress rates against the full-year company forecasts (Revenue of ¥3兆7,850.0B, Operating Income of ¥520.0B, and Ordinary Income of ¥690.0B) were 76.9% for Revenue, 83.0% for Operating Income, and 88.9% for Ordinary Income. Progress in Operating Income and Ordinary Income exceeded the standard 75% level, with Ordinary Income in particular advancing ahead of schedule due to gains on the sale of investment securities and non-operating income. Profit Attributable to Owners of the Parent was ¥374.1B against the full-year forecast of ¥345.0B, representing progress of 108.4%; however, because this includes ¥99.7B in gains on the sale of investment securities, the excess includes temporary factors that warrant attention.

Shareholder Returns

The company’s full-year dividend forecast is ¥64.00 per share, and the Q2 dividend was ¥32.00, equivalent to 50% of the full-year forecast. Based on the full-year forecast of Profit Attributable to Owners of the Parent of ¥345.0B and the average number of shares outstanding during the period of 206.2 million shares, the total annual dividend is estimated at approximately ¥132.0B, resulting in an estimated Payout Ratio of approximately 38.2%. This level is below the general sustainability benchmark of 60%, indicating a moderate dividend burden based on the earnings forecast. However, because cumulative profit includes gains on the sale of investment securities, dividend sustainability should preferably be evaluated in light of recurring earnings generation capacity.

Risk Factors

1. Declining profitability in the core business: Although the Wholesale Business of Prescription Pharmaceuticals, etc. recorded revenue growth of +3.6% year on year, segment profit declined △9.6%, and its profit margin fell from 1.2% to 1.0%, making it the primary factor pressuring consolidated Operating Income.

2. Sensitivity arising from the low-margin structure: With a low-margin structure characterized by a Gross Profit margin of 6.8% and an Operating Income margin of 1.5%, even small changes in procurement terms, logistics costs, and personnel expenses can have a significant impact on profit. Salaries and allowances account for 41.0% of SG&A expenses.

3. Working capital and collection risk: Accounts receivable of ¥8,822.8B account for 43.7% of total assets, and the scale of working capital is substantial when combined with accounts payable of ¥1,106.3B. Changes in the credit environment of business counterparties could affect both liquidity and profitability.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Growth and Capital Efficiency

※Source: Compiled by the Company

Key Takeaways from the Results

1. While Revenue expanded by +3.7% year on year, Operating Income declined △4.8%, highlighting the structural feature of these results: revenue growth did not translate into higher Operating Income. The primary cause was the decline in the profit margin of the core Wholesale Business of Prescription Pharmaceuticals, etc.

2. Growth in Ordinary Income (+8.1%) and Net Income (+1.3%) was supported by non-recurring and investment-related factors, such as ¥201.6B in non-operating income and ¥99.7B in gains on the sale of investment securities, and therefore needs to be distinguished from improvement on an Operating Income basis.

3. Progress against the full-year forecast was 83.0% for Operating Income and 88.9% for Ordinary Income, exceeding the standard 75% progress level. However, Profit Attributable to Owners of the Parent had reached 108.4% including gains on the sale of investment securities, making it important in future results reviews to assess actual earnings progress excluding temporary gains.

Theoretical Share Price (Reference Value)

Sensitivity: ¥2,760–¥2,920 for ±1% in the Cost of Equity, and ¥2,828–¥2,845 for ±0.1 in ω.

Notes:

• Because progress in Net Income against the full-year forecast (108%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies whose progress is ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net Assets at the end of the quarter are used (there is a time lag relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, where necessary, after consulting with a professional.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 results were operationally softer despite continued top-line expansion and stronger ordinary income. Revenue increased 3.7% YoY to ¥2,911.7bn. Operating income declined 4.8% YoY to ¥43.2bn, demonstrating that revenue growth did not translate into operating-profit growth. The operating margin compressed by 13bp YoY to 1.48% from 1.62%. Gross profit rose 2.5% to ¥199.0bn, but the gross margin narrowed by 8bp to 6.84%. SG&A expenses increased 4.7% to ¥155.8bn, outpacing revenue growth by roughly 1.0ppt. This SG&A deleverage was the immediate cause of the operating-income decline. Ordinary income nevertheless rose 8.1% to ¥61.3bn, supported by non-operating income of ¥20.2bn. Equity-method earnings of affiliates increased sharply to ¥3.2bn from ¥0.6bn, while gains on investments in partnerships were ¥3.8bn. Profit before tax increased only 1.0% to ¥66.6bn because extraordinary gains were substantially offset by restructuring costs and other extraordinary losses. The ¥10.0bn gain on sale of investment securities was a significant contributor to earnings above the operating line. Profit attributable to owners of parent rose 3.2% to ¥37.4bn, but its growth was therefore lower quality than a purely operating-led improvement. The annualized DuPont ROE was 6.4%, below the 8% benchmark, reflecting the structurally thin 1.3% net margin rather than weak asset utilization. The pharmaceutical wholesale business remained the largest revenue contributor, while cosmetics, daily necessities and OTC pharmaceuticals generated the largest segment profit. The balance sheet remains liquid, with a 124.9% current ratio and 106.3% quick ratio, although the working-capital base expanded materially. Full-year sales guidance appears broadly achievable, whereas Q3 cumulative parent profit has already exceeded the full-year forecast. The central issue for the outlook is whether management can restore operating-margin discipline while reducing reliance on non-operating and securities-sale gains.

Profitability Analysis

The supplied annualized DuPont framework produces ROE of 6.4%, comprising a 1.3% net profit margin, 1.922x asset turnover and 2.58x financial leverage. Asset turnover is strong for a high-volume wholesale model and is the principal offset to the low-margin earnings structure. Financial leverage also supports ROE, but the primary limiting factor is the very low net margin. Operating margin fell to 1.48% from 1.62%, a 13bp YoY contraction, while gross margin fell to 6.84% from 6.92%, an 8bp contraction. Revenue growth of 3.7% was exceeded by SG&A growth of 4.7%, indicating negative operating leverage. Salaries and allowances increased to ¥63.8bn from ¥62.3bn, and rent expense increased to ¥4.3bn from ¥3.8bn, contributing to cost pressure. The low operating-efficiency alert is relevant because the 1.5% EBIT margin is below the 5% generic benchmark; however, narrow margins are structurally characteristic of pharmaceutical and consumer-goods wholesale, making margin direction more informative than the absolute cross-industry benchmark. Segment performance confirms broad operating pressure: pharmaceutical wholesale segment profit declined 9.6% YoY to ¥18.9bn, cosmetics/daily necessities/OTC profit fell 2.2% to ¥21.9bn, and animal pharmaceuticals/food-processing materials profit rose 8.3% to ¥2.1bn. Cosmetics/daily necessities/OTC was the core business by segment-profit contribution, with a 2.31% segment margin versus 1.01% in pharmaceutical wholesale. The low gross-margin alert similarly reflects the wholesale business model, but the 8bp gross-margin decline makes the alert relevant to earnings momentum. Ordinary income growth was not matched by operating income growth, because non-operating items, including ¥3.2bn of equity-method income and ¥3.8bn of partnership investment gains, supported the result. The high-tax-burden alert is best interpreted through attributable profit: parent-attributable profit represented 56.2% of profit before tax, although the reported consolidated income-tax expense was ¥20.8bn, equivalent to a 31.2% effective tax rate on ¥66.6bn of profit before tax.

Growth Assessment

Revenue growth was broad-based across the two largest segments. Pharmaceutical wholesale revenue increased 3.6% YoY to ¥1,872.3bn, and cosmetics/daily necessities/OTC revenue increased 4.4% to ¥950.4bn. Animal pharmaceuticals and food-processing materials revenue declined 0.5% to ¥89.0bn. The revenue mix therefore remains anchored in pharmaceutical wholesale, which accounted for approximately 64% of consolidated sales. The stronger 4.4% growth in cosmetics/daily necessities/OTC did not prevent segment profit from declining, indicating cost or mix pressure despite better sales momentum. Consolidated gross profit grew only 2.5%, below revenue growth, showing that the incremental sales mix was not margin-accretive. Ordinary income grew 8.1%, but the improvement was materially assisted by non-operating income rather than a recovery in the core operating margin. The ¥10.0bn securities-sale gain was larger than the ¥5.3bn net extraordinary gain and was partly offset by ¥4.5bn restructuring costs and ¥0.4bn impairment losses. This composition means reported parent-profit growth of 3.2% overstates the underlying operating trend. Against FY2026 guidance, Q3 cumulative sales represent 76.9% of the ¥3,785.0bn full-year target, 1.9ppt above the standard 75% Q3 progress rate. Operating income progress is 83.0% of the ¥52.0bn forecast, 8.0ppt above the standard rate, but remains consistent with a full-year operating-income decline of 6.5% embedded in guidance. Ordinary income progress is 88.9% of the ¥69.0bn forecast, 13.9ppt above the standard rate, reflecting the non-operating contribution. Parent-attributable profit of ¥37.4bn is already 108.4% of the ¥34.5bn full-year forecast, exceeding the forecast by ¥2.9bn. This divergence requires attention because the forecast EPS of ¥167.63 is below the Q3 cumulative EPS of ¥181.48, implying either substantial expected Q4 losses, conservative guidance, or forecast items not apparent in the cumulative result.

Financial Health

Liquidity is adequate for the working-capital-intensive wholesale model. The current ratio was 124.9%, comfortably above 1.0x, and the quick ratio was 106.3%, indicating that cash and receivables broadly cover current obligations without depending on inventory liquidation. Working capital was positive at ¥293.3bn. Current liabilities were dominated by trade payables of ¥1,106.3bn, which represented approximately 94% of current liabilities and are consistent with a high-volume distribution model. Accounts receivable totaled ¥882.3bn and inventories totaled ¥219.5bn, while cash and deposits were ¥275.9bn. Total liabilities-to-equity D/E was 1.58x, below the 2.0x explicit warning threshold but indicative of meaningful balance-sheet leverage. Interest coverage was exceptionally strong at 4,798x because interest expense was only ¥0.009bn, limiting immediate financing-cost sensitivity. Total equity increased 3.4% YoY to ¥783.9bn, while total assets increased 10.7% to ¥2,019.4bn; consequently, the capital adequacy ratio decreased to 31.8% from 33.9%. Goodwill was only ¥12.2bn, equal to 1.6% of equity and 0.6% of assets, so the balance sheet has limited dependence on acquired goodwill values. Intangible assets were also modest at 1.9% of total assets. The principal financial-health consideration is not near-term liquidity but the faster expansion of operating working capital and liabilities relative to equity.

Notable B/S Changes

Total assets: +¥194.4bn (+10.7% YoY) to ¥2,019.4bn - balance-sheet expansion outpaced equity growth and reduced the capital adequacy ratio to 31.8%. Accounts receivable: +¥118.7bn (+15.6% YoY) to ¥882.3bn - growth substantially exceeded revenue growth, consistent with the 83-day DSO alert and requiring monitoring of collection efficiency. Inventories: +¥41.4bn (+23.2% YoY) to ¥219.5bn - inventory growth materially exceeded sales growth, raising inventory-turn and working-capital risk. Accounts payable: +¥174.2bn (+18.7% YoY) to ¥1,106.3bn - supplier credit funded much of the working-capital increase, increasing dependence on stable payment terms. Total equity: +¥26.0bn (+3.4% YoY) to ¥783.9bn - equity accumulation was positive but lagged asset growth. Investment securities: +¥13.7bn (+6.9% YoY) to ¥212.8bn - the sizable investment portfolio remains relevant given the ¥10.0bn gain on sale of investment securities recorded during the period.

Cash Flow Quality

The balance-sheet movements indicate elevated working-capital funding needs. Trade receivables increased ¥118.7bn YoY, or 15.6%, to ¥882.3bn, materially faster than 3.7% revenue growth. Inventories increased ¥41.4bn, or 23.2%, to ¥219.5bn, also well ahead of sales growth. The high-receivable-days alert is therefore material: reported DSO of 83 days exceeds the 60-day benchmark and lengthens the period over which sales are converted into cash. For a pharmaceutical wholesaler, substantial receivables are a normal feature of the distribution model, but the pace of receivable growth raises collection-efficiency and cash-conversion risk. Trade payables increased ¥174.2bn, or 18.7%, to ¥1,106.3bn, partially funding receivable and inventory growth. This payable expansion reduces immediate liquidity pressure, but it increases dependence on supplier-credit terms and continued inventory turnover. The positive quick ratio of 106.3% provides a buffer against a moderate deterioration in working-capital conversion. Reported earnings include ¥10.0bn of gain on sale of investment securities and ¥3.8bn of partnership investment gains, which are less recurring than operating profit and should be separated from assessment of recurring cash-generative capacity. The ¥4.5bn restructuring cost and ¥0.4bn impairment loss also show that the period included material non-core charges. Cash-flow quality should therefore be assessed primarily through subsequent receivable collection, inventory normalization and the recurrence of investment-related gains.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥32 per share. The full-year dividend forecast is ¥64 per share, implying an expected year-end dividend of ¥32 per share if maintained. Based on forecast EPS of ¥167.63, the forecast dividend payout ratio is approximately 38.2%, which is below the 60% sustainability benchmark. The disclosed interim-only calculated payout ratio of 18.5% also indicates conservative distribution relative to cumulative earnings. Parent-attributable earnings of ¥37.4bn already exceed the ¥34.5bn full-year forecast, providing substantial accounting-earnings coverage for the stated ¥64 annual dividend. Retained earnings were ¥479.4bn, providing an additional capital buffer. Dividend sustainability is supported by the moderate forecast payout ratio, strong interest coverage and positive working capital. The key variable for distribution capacity is the working-capital burden, particularly receivables and inventories, rather than the reported payout ratio alone. No total return ratio is calculated because no share-buyback amount is provided.

Risk Assessment

Business risks include Margin compression risk: consolidated operating margin declined 13bp YoY to 1.48%, with gross margin down 8bp and SG&A growth of 4.7% exceeding revenue growth of 3.7%., Pharmaceutical wholesale profitability risk: the largest sales segment recorded a 9.6% YoY decline in segment profit to ¥18.9bn despite 3.6% revenue growth., Working-capital execution risk: receivables rose 15.6% and inventories 23.2%, materially faster than sales, while reported DSO of 83 days exceeds the 60-day benchmark., Wholesale-industry risk: regulated pricing, reimbursement revisions, purchasing terms and competition can compress already thin distributor margins., Earnings-recurringness risk: ordinary-income growth was supported by equity-method earnings, partnership investment gains and a ¥10.0bn gain on sale of investment securities..

Financial risks include Capital adequacy declined to 31.8% from 33.9% as total assets expanded 10.7%, faster than total equity growth of 3.4%., D/E of 1.58x is below the 2.0x warning threshold but leaves the company more reliant on liabilities than a conservatively financed peer., Trade payables increased ¥174.2bn YoY, making liquidity increasingly dependent on supplier financing and stable payment terms., The 1.3% net margin offers limited earnings protection against modest adverse changes in pricing, product mix or operating costs..

Key concerns include The low operating-efficiency alert is confirmed by a 1.5% EBIT margin; this is structurally common in wholesale but its YoY deterioration is negative., The low gross-margin alert is confirmed by the 6.8% gross margin; the key concern is the 8bp YoY decline rather than the absolute level alone., The high-receivable-days alert is confirmed by 83-day DSO and receivable growth well above revenue growth, creating a cash-conversion monitoring priority., The high-tax-burden alert is relevant on a parent-attributable-profit basis, where the tax-burden measure is 0.562; the consolidated reported effective tax rate was 31.2%, so the period does not show a 44% consolidated cash-tax rate., Q3 cumulative parent profit exceeded full-year guidance by 8.4%, creating uncertainty around the conservatism and composition of the remaining forecast..

Investment Implications

Key takeaways include Revenue growth remains intact, but operating profit and margins are declining., Cosmetics/daily necessities/OTC is the core business by segment profit, generating ¥21.9bn of segment profit and a 2.31% margin., Ordinary-income strength was supported by non-operating and investment-related income rather than a recovery in core operating profitability., Liquidity is adequate, but receivables, inventory and payables are expanding rapidly., The forecast dividend implies a moderate 38.2% payout ratio based on forecast EPS..

Metrics to watch include Consolidated operating margin and gross-margin trend, Pharmaceutical wholesale segment profit recovery, SG&A growth relative to revenue growth, DSO, trade-receivable growth and inventory growth, Trade-payable growth and current-ratio trend, Magnitude and recurrence of securities-sale gains, partnership gains and equity-method earnings, Any revision to the ¥34.5bn full-year parent-profit forecast.

Regarding relative positioning, Medipal exhibits the high asset-turnover, low-margin profile typical of a large Japanese healthcare and consumer-products wholesaler. Its 1.922x annualized asset turnover and adequate liquidity are relative strengths, while a 1.48% operating margin, 6.4% annualized ROE and elevated 83-day DSO make margin execution and working-capital discipline the principal relative differentiators.